Dominic Borie
Hoofd Techniek/Wetenschap/O&O bij KYVERNA THERAPEUTICS, INC.
Vermogen: 7 M $ op 30-04-2024
Profiel
Dominic Borie is currently the President-Research & Development at Kyverna Therapeutics, Inc. He previously worked as an Executive Director at Allogene Therapeutics, Inc., a Medical Director at Amgen, Inc., a Senior Medical Director at Genentech, Inc., and a VP, Head-External Research & Development at Horizon Therapeutics Plc.
Dr. Borie also served as the Director-Transplantation Immunology Laboratory at Stanford University.
He holds a doctorate degree from The University of Texas at Austin and an undergraduate degree from North Carolina State University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 07-02-2024 | 449 210 ( 1.04% ) | 7 M $ | 30-04-2024 |
Actieve functies van Dominic Borie
| Bedrijven | Functie | Begin |
|---|---|---|
| KYVERNA THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 13-10-2022 |
Eerdere bekende functies van Dominic Borie
| Bedrijven | Functie | Einde |
|---|---|---|
| Stanford University | Corporate Officer/Principal | - |
| AMGEN INC. | Hoofd Techniek/Wetenschap/O&O | - |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Corporate Officer/Principal | - |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
| ALLOGENE THERAPEUTICS, INC. | Directeur/Bestuurslid | - |
Opleiding van Dominic Borie
| The University of Texas at Austin | Doctorate Degree |
| North Carolina State University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| KYVERNA THERAPEUTICS, INC. | Health Technology |
| ALLOGENE THERAPEUTICS, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |